Arrowhead’s Redemplo Wins UK Approval to Treat FCS
Arrowhead said its plozasiran treatment, marketed as Redemplo, received approval in the United Kingdom for familial chylomicronemia syndrome (FCS).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.